Meningococcal B vaccine under TGA review
“It is the holy grail. It is the last big cause of meningitis and blood poisoning,” said Professor Robert Booy, head of clinical research at the National Centre for Immunisation Research and Surveillance, Sydney.
The vaccine, called Bexsero (Novartis), has been approved by the European Commission for use in infants from two months.
The European Medicines Agency said it was the first vaccine to provide broad coverage against meningococcal group B strains.
The sponsor confirmed the vaccine was under review by the TGA.